Niagen Bioscience (NAGE) Long-Term Investments (2013 - 2016)

Niagen Bioscience's (NAGE) quarterly Long-Term Investments came in at $20318.0 in Q4 2016, little changed on a QoQ basis from $20318.0 in Q4 2016.

Niagen Bioscience (NAGE) Long-Term Investments (2013 - 2016) Analysis & Trends

Niagen Bioscience (NAGE) has 2 years of Long-Term Investments data on file, last reported at $20318.0 in Q4 2016.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $20318.0 in Q4 2016; TTM through Dec 2016 was $20318.0, a N/A change from a year earlier, with the FY2016 full-year figure at $20318.0, changed N/A from the prior year.
Long-Term Investments for Q4 2016 stood at $20318.0, roughly flat from $20318.0 in the prior quarter.
Over the last five years, Long-Term Investments for NAGE reached as high as $2.7 million in Q1 2013 and fell as low as $20318.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Niagen Bioscience	253.47 Mn	186.92 Mn	19.98 Mn	-

Download Data